Mylan, Ethypharm Strike Deal In FazaClo Patent Spat

Law360, New York (January 18, 2011, 5:44 PM EST) -- Mylan Pharmaceuticals Inc. has agreed to end its declaratory judgment suit against Ethypharm SA over the schizophrenia drug FazaClo, with the drug companies entering a stipulated judgment that Mylan's generic medication would not infringe Ethypharm's patent.

Judge Leonard P. Stark signed off on the final judgment in the U.S. District Court for the District of Delaware on Thursday, declaring that Mylan's products that are the subject of its abbreviated new drug application for a generic version of FazaClo do not infringe any claim of U.S. Patent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.